Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dolutegravir Effect on Insulin Sensitivity and Metabolism (DTG Clamp)
NCT04771754Phase 1Completed
- Sponsor
- Chelsea and Westminster Hospital NHS Foundation Trust
- Start
- Mar 2022
- Primary completion
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of dolutegravir in human immunodeficiency virus infection (HIV), sponsored by Chelsea and Westminster Hospital NHS Foundation Trust. Started Mar 2022; status: completed.
02
Drugs
dolutegravir
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT04771754.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04771754.